Spectrums Europe has announced a “major step” towards regulatory approval of its CBD ingredients in Europe. The novel food applications of the company’s Broad Extract 85% + and its CBD Isolate Powder 99% have been declared valid by the European authorities.
This step precedes a formal request that the European Food Safety Authority (EFSA) assess the relevance of the data submitted. This is the last step before the EFSA opinion on the safety of the company’s ingredients, a notice due by November 2022.
Despite numerous CBD food products already on the market, CBD and broad spectrum extracts are considered novel food and therefore subject to prior authorisation by EFSA. Unlike Spectrums’ applications, the company says, a large number of the dossiers submitted to EFSA are not yet under evaluation. The progress in its applications helps the company support our customers in the development of products in compliance with the regulations.
